JUNSHI BIO: The clinical trial application for injectable JS212 has been approved.

CKH HOLDINGS (00001.HK): The profit contribution from the operating Business of CKH HOLDINGS recorded a strong growth of 10% year-on-year. However, the net profit was affected by financial items (including increased interest costs and decreased exchange gains), resulting in the reported net profit based on IFRS 16 being HKD 8.115 billion, an increase of 1% from last year. Looking ahead to 2025, the regulated businesses in this sector will continue to provide stable recurring income, while the non-regulated businesses will also contribute good growth. Capital expenditures and new investments will be limited, with a focus on strict cash flow management.

Iran's Foreign Minister: President Trump's letter is "more of a threat," but at the same time "claims that there is an opportunity," and Iran will think about this.